RxDoctor Payments Data

Jack Braha, DO

Gastroenterology · Brooklyn, NYNPI 1548456890

Payments from drug & device makers

$89,236in general payments, 2019–2025

Across 153 payments — averaging $583.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$77K
  • AbbVie$12K
  • Madrigal Pharmaceuticals$143
  • Johnson & Johnson$91
  • Aimmune Therapeutics, Inc.$86
  • Cumberland Pharmaceuticals, Inc.$61
  • plus $169 from 6 others

What the payments were for

  • Speaking & faculty fees$82,34092%
  • Grants$200%
  • Travel & lodging$3,0713%
  • Food & beverage$3,8054%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,236 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$372,567
Medicare patients
723
Services billed
3,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide107$86,995
VoqueznaVonoprazan Fumarate80$57,026
ZenpepLipase/Protease/Amylase21$51,708
Mesalamine43$34,753
XifaxanRifaximin13$27,966
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates290$16,369
TrulancePlecanatide14$8,691
Pantoprazole Sodium470$4,341
Vancomycin Hcl14$3,849
Ursodiol37$3,631
Sucralfate22$2,839
Lubiprostone18$1,925
Omeprazole150$1,725
Esomeprazole Magnesium23$1,413
CholestyramineCholestyramine (With Sugar)32$1,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$12,105$86,995107 claims
Phathom Pharmaceuticals, Inc.Voquezna$76,581$57,02680 claims
Aimmune Therapeutics, Inc.Zenpep$86$51,70821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →